Phaseline

Targets › GSS

GSS (Glutathione synthetase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Sep 2027.

Catalyzes the production of glutathione from gamma-glutamylcysteine and glycine in an ATP-dependent manner. Glutathione (gamma-glutamylcysteinylglycine, GSH) is the most abundant intracellular thiol in living aerobic cells and is required for numerous processes including the protection of cells against oxidative damage, amino acid transport, the detoxification of foreign compounds, the maintenance of protein…. (UniProt, P48637)

Open in Phaseline: the race on GSS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gateway Institute for Brain ResearchINS-GSH
Intranasal insulin and glutathione combination
INS, GSSPhase 2Parkinson DiseaseSep 2027

Conditions

Parkinson Disease (1)

Modalities

small molecule (1)

Companies

Gateway Institute for Brain Research (1)

Related targets

INS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.